Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
Genentech advances enicepatide and petrelintide obesity data at ADA 2026. Find out why Roche’s strategy matters now.
Pharma & Biotech
Pharma & Biotech
Can Scribe Therapeutics make one-dose LDL-C lowering a practical CRISPR frontier?
Find out how Scribe Therapeutics’ STX-1150 could reshape long-acting LDL-C lowering through CRISPR-based epigenetic silencing.
Pharma & Biotech
Scribe Therapeutics brings specificity challenge into focus for CRISPR cardiometabolic drugs
CRISPR can lower cholesterol. The harder test is whether Scribe can make durability, precision, and scalability work in common disease.
Pharma & Biotech
GSK’s $1bn SiranBio pact raises the stakes in extrahepatic siRNA delivery
GLP-1 drugs dominate obesity. GSK is betting SiranBio’s SA030 can attack visceral fat risk from a different angle.
Pharma & Biotech
Why MetaVia’s higher-dose titration strategy could matter more than the first-patient milestone itself
MetaVia has started higher-dose testing for DA-1726 in obesity. Read what this means for tolerability, competition, and the next clinical milestone.
Pharma & Biotech
Can Merck’s enlicitide decanoate become the oral PCSK9 breakthrough cholesterol care has been waiting for?
Merck’s enlicitide decanoate beat oral rivals in Phase 3. Read what this could change for cholesterol care, PCSK9 adoption, and market strategy.
Pharma & Biotech
Can Merck expand WINREVAIR beyond pulmonary arterial hypertension after CADENCE data?
Can Merck turn WINREVAIR’s CADENCE data into a new treatment path in CpcPH-HFpEF? Read the full analysis of what changes next.
Pharma & Biotech
Scribe Therapeutics deepens in vivo CRISPR validation with second Eli Lilly collaboration milestone
Scribe Therapeutics hits a second in vivo CRISPR milestone with Eli Lilly. Explore what this changes for gene editing platforms and future therapies.